Matthew Schmidt

Matthew Schmidt is director of regulatory affairs at Verve Therapeutics. He has over 6 years of experience in regulatory strategy, within the life sciences industry across all stages of product development and with multiple therapeutic areas. Prior to joining Verve, Dr. Schmidt was an associate director of regulatory strategy at bluebird bio, Inc. supporting the development and marketing approval of an autologous gene therapy product for a rare genetic disease. Dr. Schmidt earned his Doctor of Pharmacy (Pharm.D.) from Northeastern University and is a Registered Pharmacist in the Commonwealth of Massachusetts. He was a postdoctoral fellow at Genentech, A Member of the Roche Group, in the Rutgers Institute for Pharmaceutical Industry Fellowships Program.